Table of Contents
Journal of Signal Transduction
Volume 2011 (2011), Article ID 982879, 11 pages
http://dx.doi.org/10.1155/2011/982879
Review Article

Receptor-Tyrosine-Kinase-Targeted Therapies for Head and Neck Cancer

1Departments of Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, TX 77555-1074, USA
2Department of Otolaryngology and UTMB Cancer Center, University of Texas Medical Branch, Galveston, TX 77555, USA

Received 7 January 2011; Accepted 5 April 2011

Academic Editor: Bertrand Jean-Claude

Copyright © 2011 Lisa A. Elferink and Vicente A. Resto. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. A. Molinolo, P. Amornphimoltham, C. H. Squarize, R. M. Castilho, V. Patel, and J. S. Gutkind, “Dysregulated molecular networks in head and neck carcinogenesis,” Oral Oncology, vol. 45, no. 4-5, pp. 324–334, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Bernier, S. M. Bentzen, and J. B. Vermorken, “Molecular therapy in head and neck oncology,” Nature Reviews Clinical Oncology, vol. 6, no. 5, pp. 266–277, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. C. R. Leemans, B. J.M. Braakhuis, and R. H. Brakenhoff, “The molecular biology of head and neck cancer,” Nature Reviews Cancer, vol. 11, no. 1, pp. 9–22, 2011. View at Publisher · View at Google Scholar
  4. C. H. Chung, J. S. Parker, G. Karaca et al., “Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression,” Cancer Cell, vol. 5, no. 5, pp. 489–500, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. O. B. Bleijerveld, R. H. Brakenhoff, T. B. M. Schaaij-Visser et al., “Protein signatures associated with tumor cell dissemination in head and neck cancer,” Journal of Proteomics, vol. 74, no. 4, pp. 558–566, 2011. View at Publisher · View at Google Scholar
  6. P. Choi, C. D. Jordan, E. Mendez et al., “Examination of oral cancer biomarkers by tissue microarray analysis,” Archives of Otolaryngology—Head and Neck Surgery, vol. 134, no. 5, pp. 539–546, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Forastiere, W. Koch, A. Trotti, and D. Sidransky, “Head and neck cancer,” The New England Journal of Medicine, vol. 345, no. 26, pp. 1890–1900, 2001. View at Google Scholar · View at Scopus
  8. T. M. Goldson, Y. Han, K. B. Knight, H. L. Weiss, and V. A. Resto, “Clinicopathological predictors of lymphatic metastasis in HNSCC: implications for molecular mechanisms of metastatic disease,” Journal of Experimental Therapeutics and Oncology, vol. 8, no. 3, pp. 211–221, 2010. View at Google Scholar · View at Scopus
  9. S. W. Chan, B. N. Mukesh, and A. Sizeland, “Treatment outcome of N3 nodal head and neck squamous cell carcinoma,” Otolaryngology—Head and Neck Surgery, vol. 129, no. 1, pp. 55–60, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. J. G. Spector, D. G. Sessions, B. H. Haughey et al., “Delayed regional metastases, distant metastases, and second primary malignancies in squamous cell carcinomas of the larynx and hypopharynx,” Laryngoscope, vol. 111, no. 6, pp. 1079–1087, 2001. View at Google Scholar · View at Scopus
  11. D. W. Klotch, C. Muro-Cacho, and T. J. Gal, “Factors affecting survival for floor-of-mouth carcinoma,” Otolaryngology—Head and Neck Surgery, vol. 122, no. 4, pp. 495–498, 2000. View at Google Scholar · View at Scopus
  12. K. D. Olsen, M. Caruso, R. L. Foote et al., “Primary head and neck cancer: histopathologic predictors of recurrence after neck dissection in patients with lymph node involvement,” Archives of Otolaryngology—Head and Neck Surgery, vol. 120, no. 12, pp. 1370–1374, 1994. View at Google Scholar · View at Scopus
  13. D. G. Sessions, J. Lenox, G. J. Spector, C. Chao, and O. A. Chaudry, “Analysis of treatment results for base of tongue cancer,” Laryngoscope, vol. 113, no. 7, pp. 1252–1261, 2003. View at Google Scholar · View at Scopus
  14. D. G. Sessions, G. J. Spector, J. Lenox, B. Haughey, C. Chao, and J. Marks, “Analysis of treatment results for oral tongue cancer,” Laryngoscope, vol. 112, no. 4, pp. 616–625, 2002. View at Google Scholar · View at Scopus
  15. D. G. Sessions, G. J. Spector, J. Lenox et al., “Analysis of treatment results for floor-of-mouth cancer,” Laryngoscope, vol. 110, no. 10, pp. 1764–1772, 2000. View at Google Scholar · View at Scopus
  16. C. H. Shiboski, B. L. Schmidt, and R. C. K. Jordan, “Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20–44 years,” Cancer, vol. 103, no. 9, pp. 1843–1849, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Jemal, R. Siegel, J. Xu, and E. Ward, “Cancer statistics, 2010,” CA Cancer Journal for Clinicians, vol. 60, no. 5, pp. 277–300, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Davies and H. G. Welch, “Epidemiology of head and neck cancer in the United States,” Otolaryngology—Head and Neck Surgery, vol. 135, no. 3, pp. 451–457, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. A. L. Carvalho, I. N. Nishimoto, J. A. Califano, and L. P. Kowalski, “Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database,” International Journal of Cancer, vol. 114, no. 5, pp. 806–816, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. G. M. Poage, B. C. Christensen, E. A. Houseman et al., “Genetic and epigenetic somatic alterations in head and neck squamous cell carcinomas are globally coordinated but not locally targeted,” PLoS One, vol. 5, no. 3, Article ID e9651, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the next generation,” Cell, vol. 144, no. 5, pp. 646–647, 2011. View at Google Scholar
  22. D. Hanahan and R. A. Weinberg, “The hallmarks of cancer,” Cell, vol. 100, no. 1, pp. 57–70, 2000. View at Google Scholar · View at Scopus
  23. P. Blume-Jensen and T. Hunter, “Oncogenic kinase signalling,” Nature, vol. 411, no. 6835, pp. 355–365, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Hunter, “Tyrosine phosphorylation: thirty years and counting,” Current Opinion in Cell Biology, vol. 21, no. 2, pp. 140–146, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Manning, D. B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam, “The protein kinase complement of the human genome,” Science, vol. 298, no. 5600, pp. 1912–1934, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. J. R. Grandis and D. J. Tweardy, “Elevated levels of transforming growth factor α and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer,” Cancer Research, vol. 53, no. 15, pp. 3579–3584, 1993. View at Google Scholar · View at Scopus
  27. A. Cavalot, T. Martone, N. Roggero, G. Brondino, M. Pagano, and G. Cortesina, “Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas,” Head and Neck, vol. 29, no. 7, pp. 655–664, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Rautava, K. J. Jee, P. J. Miettinen et al., “ERBB receptors in developing, dysplastic and malignant oral epithelia,” Oral Oncology, vol. 44, no. 3, pp. 227–235, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Fung and J. R. Grandis, “Emerging drugs to treat squamous cell carcinomas of the head and neck,” Expert Opinion on Emerging Drugs, vol. 15, no. 3, pp. 355–373, 2010. View at Publisher · View at Google Scholar
  30. J. D. Klein and J. R. Grandis, “The molecular pathogenesis of head and neck cancer,” Cancer Biology and Therapy, vol. 9, no. 1, pp. 1–7, 2010. View at Google Scholar · View at Scopus
  31. J. H. Bae and J. Schlessinger, “Asymmetric tyrosine kinase arrangements in activation or autophosphorylation of receptor tyrosine kinases,” Molecules and Cells, vol. 29, no. 5, pp. 1–6, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. A. W. Burgess, “EGFR family: structure physiology signalling and therapeutic target,” Growth Factors, vol. 26, no. 5, pp. 263–274, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. R. N. Jorissen, F. Walker, N. Pouliot, T. P. J. Garrett, C. W. Ward, and A. W. Burgess, “Epidermal growth factor receptor: mechanisms of activation and signalling,” Experimental Cell Research, vol. 284, no. 1, pp. 31–53, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. N. E. Hynes and H. A. Lane, “ERBB receptors and cancer: the complexity of targeted inhibitors,” Nature Reviews Cancer, vol. 5, no. 5, pp. 341–354, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. L. Strachan, J. G. Murison, R. L. Prestidge, M. A. Sleeman, J. D. Watson, and K. D. Kumble, “Cloning and biological activity of epigen, a novel member of the epidermal growth factor superfamily,” The Journal of Biological Chemistry, vol. 276, no. 21, pp. 18265–18271, 2001. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. Yarden and M. X. Sliwkowski, “Untangling the ErbB signalling network,” Nature Reviews Molecular Cell Biology, vol. 2, no. 2, pp. 127–137, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. B. S. Kochupurakkal, D. Harari, A. Di-Segni et al., “Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity,” The Journal of Biological Chemistry, vol. 280, no. 9, pp. 8503–8512, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. J. R. Grandis and D. J. Tweardy, “TGF-α and EGFR in head and neck cancer,” Journal of Cellular Biochemistry, vol. 52, pp. 188–191, 1993. View at Google Scholar · View at Scopus
  39. T. J. Lynch, D. W. Bell, R. Sordella et al., “Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib,” The New England Journal of Medicine, vol. 350, no. 21, pp. 2129–2139, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Cortes-Funes, C. Gomez, R. Rosell et al., “Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients,” Annals of Oncology, vol. 16, no. 7, pp. 1081–1086, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. G. J. Riely, W. Pao, D. Pham et al., “Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib,” Clinical Cancer Research, vol. 12, no. 3, pp. 839–844, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. J. G. Paez, P. A. Jänne, J. C. Lee et al., “EGFR mutations in lung, cancer: correlation with clinical response to gefitinib therapy,” Science, vol. 304, no. 5676, pp. 1497–1500, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. W. Pao, V. Miller, M. Zakowski et al., “EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 36, pp. 13306–13311, 2004. View at Publisher · View at Google Scholar
  44. C. Willmore-Payne, J. A. Holden, and L. J. Layfield, “Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression,” Human Pathology, vol. 37, no. 6, pp. 755–763, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. W. L. Jong, H. S. Young, Y. K. Su et al., “Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck,” Clinical Cancer Research, vol. 11, no. 8, pp. 2879–2882, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Temam, H. Kawaguchi, A. K. El-Naggar et al., “Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer,” Journal of Clinical Oncology, vol. 25, no. 16, pp. 2164–2170, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. K. K. Ang, B. A. Berkey, X. Tu et al., “Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma,” Cancer Research, vol. 62, no. 24, pp. 7350–7356, 2002. View at Google Scholar · View at Scopus
  48. A. K. Gupta, W. G. McKenna, C. N. Weber et al., “Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction,” Clinical Cancer Research, vol. 8, no. 3, pp. 885–892, 2002. View at Google Scholar · View at Scopus
  49. S. M. Bentzen, B. M. Atasoy, F. M. Daley et al., “Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial,” Journal of Clinical Oncology, vol. 23, no. 24, pp. 5560–5567, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. J. D. Sato, T. Kawamoto, A. D. Le, J. Mendelsohn, J. Polikoff, and G. H. Sato, “Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors,” Molecular Biology & Medicine, vol. 1, no. 5, pp. 511–529, 1983. View at Google Scholar · View at Scopus
  51. T. Kawamoto, J. D. Sato, and A. Le, “Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody,” Proceedings of the National Academy of Sciences of the United States of America, vol. 80, no. 5, pp. 1337–1341, 1983. View at Google Scholar
  52. G. N. Gill, T. Kawamoto, and C. Cochet, “Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity,” The Journal of Biological Chemistry, vol. 259, no. 12, pp. 7755–7760, 1984. View at Google Scholar · View at Scopus
  53. H. Masui, T. Kawamoto, and J. D. Sato, “Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies,” Cancer Research, vol. 44, no. 3, pp. 1002–1007, 1984. View at Google Scholar · View at Scopus
  54. L. Koutcher, E. Sherman, M. Fury et al., “Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer,” International Journal of Radiation Oncology, Biology, Physics. In press. View at Publisher · View at Google Scholar
  55. D. Dequanter, M. Shahla, P. Paulus, and P. Lothaire, “Cetuximab in the treatment of head and neck cancer: preliminary results outside clinical trials,” Cancer Management and Research, vol. 2, no. 1, pp. 165–168, 2010. View at Google Scholar
  56. J. A. Bonner, P. M. Harari, J. Giralt et al., “Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck,” The New England Journal of Medicine, vol. 354, no. 6, pp. 567–578, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. C. Cripps, E. Winquist, M. C. Devries, D. Stys-Norman, and R. Gilbert, “Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer,” Current Oncology, vol. 17, no. 3, pp. 37–48, 2010. View at Google Scholar · View at Scopus
  58. R. J. Taylor, S. L. Chan, A. Wood et al., “FcγRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck,” Cancer Immunology, Immunotherapy, vol. 58, no. 7, pp. 997–1006, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Dechant, W. Weisner, S. Berger et al., “Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies,” Cancer Research, vol. 68, no. 13, pp. 4998–5003, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. J. Schmiedel, A. Blaukat, S. Li, T. Knöchel, and K. M. Ferguson, “Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization,” Cancer Cell, vol. 13, no. 4, pp. 365–373, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. U. Vanhoefer, M. Tewes, F. Rojo et al., “Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor,” Journal of Clinical Oncology, vol. 22, no. 1, pp. 175–184, 2004. View at Publisher · View at Google Scholar · View at Scopus
  62. M. O. Rodríguez, T. C. Rivero, R. D. C. Bahi et al., “Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck,” Cancer Biology and Therapy, vol. 9, no. 5, pp. 343–349, 2010. View at Google Scholar · View at Scopus
  63. M. Ranson, L. A. Hammond, D. Ferry et al., “ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial,” Journal of Clinical Oncology, vol. 20, no. 9, pp. 2240–2250, 2002. View at Publisher · View at Google Scholar · View at Scopus
  64. J. Baselga, D. Rischin, M. Ranson et al., “Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types,” Journal of Clinical Oncology, vol. 20, no. 21, pp. 4292–4302, 2002. View at Publisher · View at Google Scholar · View at Scopus
  65. L. L. Siu, D. Soulieres, E. X. Chen et al., “Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group study,” Journal of Clinical Oncology, vol. 25, no. 16, pp. 2178–2183, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. M. Pollak, “Insulin and insulin-like growth factor signalling in neoplasia,” Nature Reviews Cancer, vol. 8, no. 12, pp. 915–928, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. Y. Tao, V. Pinzi, J. Bourhis, and E. Deutsch, “Mechanisms of Disease: signaling of the insulin-like growth factor 1 receptor pathway—therapeutic perspectives in cancer,” Nature Clinical Practice Oncology, vol. 4, no. 10, pp. 591–602, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. S. Kurihara, F. Hakuno, and S. I. Takahashi, “Insulin-like growth factor-I-dependent signal transduction pathways leading to the induction of cell growth and differentiation of human neuroblastoma cell line SH-SY5Y: the roles of MAP kinase pathway and PI 3-kinase pathway,” Endocrine Journal, vol. 47, no. 6, pp. 739–751, 2000. View at Google Scholar · View at Scopus
  69. Y. Tang, D. Zhang, L. Fallavollita, and P. Brodt, “Vascular endothelial growth factor C expression and lymph node metastasis are regulated by the type I insulin-like growth factor receptor,” Cancer Research, vol. 63, no. 6, pp. 1166–1171, 2003. View at Google Scholar · View at Scopus
  70. R. E. Friedrich, C. Hagel, and S. Bartel-Friedrich, “Insulin-like growth factor-1 receptor (IGF-1R) in primary and metastatic undifferentiated carcinoma of the head and neck: a possible target of immunotherapy,” Anticancer Research, vol. 30, no. 5, pp. 1641–1643, 2010. View at Google Scholar
  71. C. J. Barnes, K. Ohshiro, S. K. Rayala, A. K. El-Naggar, and R. Kumar, “Insulin-like growth factor receptor as a therapeutic target in head and neck cancer,” Clinical Cancer Research, vol. 13, no. 14, pp. 4291–4299, 2007. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Liu, F. Jin, W. Dai, and Y. Yu, “Antisense treatment of IGF-IR enhances chemosensitivity in squamous cell carcinomas of the head and neck,” European Journal of Cancer, vol. 46, no. 9, pp. 1744–1751, 2010. View at Publisher · View at Google Scholar · View at Scopus
  73. M. Hewish, I. Chau, and D. Cunningham, “Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine,” Recent Patents on Anti-Cancer Drug Discovery, vol. 4, no. 1, pp. 54–72, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. S. J. Weroha and P. Haluska, “IGF-1 receptor inhibitors in clinical trials—early lessons,” Journal of Mammary Gland Biology and Neoplasia, vol. 13, no. 4, pp. 471–483, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. D. Sachdev, “Targeting the Type I insulin-like growth factor system for breast cancer therapy,” Current Drug Targets, vol. 11, no. 9, pp. 1121–1132, 2010. View at Publisher · View at Google Scholar
  76. A. Camirand, M. Zakikhani, F. Young, and M. Pollak, “Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells,” Breast Cancer Research, vol. 7, no. 4, pp. R570–R579, 2005. View at Google Scholar · View at Scopus
  77. H. E. Jones, L. Goddard, J. M. W. Gee et al., “Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iresa) in human breast and prostate cancer cells,” Endocrine-Related Cancer, vol. 11, no. 4, pp. 793–814, 2004. View at Publisher · View at Google Scholar · View at Scopus
  78. L. Trusolino and P. M. Comoglio, “Scatter-factor and semaphorin receptors: cell signalling for invasive growth,” Nature Reviews Cancer, vol. 2, no. 4, pp. 289–300, 2002. View at Google Scholar · View at Scopus
  79. C. Birchmeier, W. Birchmeier, E. Gherardi, and G. F. Vande Woude, “Met, metastasis, motility and more,” Nature Reviews Molecular Cell Biology, vol. 4, no. 12, pp. 915–925, 2003. View at Publisher · View at Google Scholar · View at Scopus
  80. D. Y. Chirgadze, J. P. Hepple, H. Zhou, R. Andrew Byrd, T. L. Blundell, and E. Gherardi, “Crystal structure of the NK1 fragment of HGF/SF suggests a novel mode for growth factor dimerization and receptor binding,” Nature Structural Biology, vol. 6, no. 1, pp. 72–79, 1999. View at Publisher · View at Google Scholar · View at Scopus
  81. J. Stamos, R. A. Lazarus, X. Yao, D. Kirchhofer, and C. Wiesmann, “Crystal structure of the HGF β-chain in complex with the Sema domain of the Met receptor,” The EMBO Journal, vol. 23, no. 12, pp. 2325–2335, 2004. View at Publisher · View at Google Scholar · View at Scopus
  82. M. Sattler and R. Salgia, “The MET axis as a therapeutic target,” Update on Cancer Therapeutics, vol. 3, no. 3, pp. 109–118, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. P. M. Comoglio, S. Giordano, and L. Trusolino, “Drug development of MET inhibitors: targeting oncogene addiction and expedience,” Nature Reviews Drug Discovery, vol. 7, no. 6, pp. 504–516, 2008. View at Publisher · View at Google Scholar · View at Scopus
  84. J. P. Eder, G. F. Vande Woude, S. A. Boerner, and P. M. Lorusso, “Novel therapeutic inhibitors of the c-Met signaling pathway in cancer,” Clinical Cancer Research, vol. 15, no. 7, pp. 2207–2214, 2009. View at Publisher · View at Google Scholar · View at Scopus
  85. T. Y. Seiwert, R. Jagadeeswaran, L. Faoro et al., “The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma,” Cancer Research, vol. 69, no. 7, pp. 3021–3031, 2009. View at Publisher · View at Google Scholar · View at Scopus
  86. A. J. Cowin, N. Kallincos, N. Hatzirodos et al., “Hepatocyte growth factor and macrophage-stimulating protein are upregulated during excisional wound repair in rats,” Cell and Tissue Research, vol. 306, no. 2, pp. 239–250, 2001. View at Publisher · View at Google Scholar · View at Scopus
  87. M. F. Di Renzo, M. Olivero, T. Martone et al., “Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas,” Oncogene, vol. 19, no. 12, pp. 1547–1555, 2000. View at Google Scholar · View at Scopus
  88. G. Cortesina, T. Martone, E. Galeazzi et al., “Staging of head and neck squamous cell carcinoma using the MET oncogene product as marker of tumor cells in lymph node metastases,” International Journal of Cancer, vol. 89, no. 3, pp. 286–292, 2000. View at Publisher · View at Google Scholar · View at Scopus
  89. J. B. Tuynman, S. M. Lagarde, F. J. W. Ten Kate, D. J. Richel, and J. J. B. Van Lanschot, “Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma,” British Journal of Cancer, vol. 98, no. 6, pp. 1102–1108, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. C. -H. Kim, Y. W. Koh, J. H. Han et al., “C-Met expression as an indicator of survival outcome in patients with oral tongue carcinoma,” Head and Neck, vol. 32, no. 12, pp. 1655–1664, 2010. View at Publisher · View at Google Scholar
  91. L. M. Knowles, L. P. Stabile, A. M. Egloff et al., “HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer,” Clinical Cancer Research, vol. 15, no. 11, pp. 3740–3750, 2009. View at Publisher · View at Google Scholar · View at Scopus
  92. T. Kakkar, M. Ma, Y. Zhuang, A. Patton, Z. Hu, and B. Mounho, “Pharmacokinetics and safety of a fully human hepatocyte growth factor antibody, AMG 102, in cynomolgus monkeys,” Pharmaceutical Research, vol. 24, no. 10, pp. 1910–1918, 2007. View at Publisher · View at Google Scholar · View at Scopus
  93. M. S. Gordon, C. S. Sweeney, D. S. Mendelson et al., “Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors,” Clinical Cancer Research, vol. 16, no. 2, pp. 699–710, 2010. View at Publisher · View at Google Scholar · View at Scopus
  94. P. J. Rosen, C. J. Sweeney, D. J. Park et al., “A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors,” Clinical Cancer Research, vol. 16, no. 9, pp. 2677–2687, 2010. View at Publisher · View at Google Scholar · View at Scopus
  95. H. Jin, R. Yang, Z. Zheng et al., “MetMAb, the one-armed 5d5 anti-c-met antibody, inhibits orthotopic pancreatic tumor growth and improves survival,” Cancer Research, vol. 68, no. 11, pp. 4360–4368, 2008. View at Publisher · View at Google Scholar · View at Scopus
  96. T. Martens, N. O. Schmidt, C. Eckerich et al., “A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo,” Clinical Cancer Research, vol. 12, no. 20, pp. 6144–6152, 2006. View at Publisher · View at Google Scholar · View at Scopus
  97. F. Qian, S. Engst, K. Yamaguchi et al., “Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases,” Cancer Research, vol. 69, no. 20, pp. 8009–8016, 2009. View at Publisher · View at Google Scholar · View at Scopus
  98. N. Munshi, S. Jeay, Y. Li et al., “ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity,” Molecular Cancer Therapeutics, vol. 9, no. 6, pp. 1544–1553, 2010. View at Publisher · View at Google Scholar · View at Scopus
  99. R. Bagai, W. Fan, and P. C. Ma, “ARQ-197, an oral small-molecule inhibitor of c-met for the treatment of solid tumors,” IDrugs, vol. 13, no. 6, pp. 404–414, 2010. View at Google Scholar · View at Scopus
  100. S. H. Bigner, P. A. Humphrey, A. J. Wong et al., “Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts,” Cancer Research, vol. 50, no. 24, pp. 8017–8022, 1990. View at Google Scholar · View at Scopus
  101. D. K. Moscatello, M. Holgado-Madruga, D. R. Emlet, R. B. Montgomery, and A. J. Wong, “Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor,” The Journal of Biological Chemistry, vol. 273, no. 1, pp. 200–206, 1998. View at Publisher · View at Google Scholar · View at Scopus
  102. R. J. Leeman-Neill, S. E. Wheeler, S. V. Singh et al., “Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3,” Carcinogenesis, vol. 30, no. 11, pp. 1848–1856, 2009. View at Publisher · View at Google Scholar
  103. S. E. Wheeler, S. Suzuki, S. M. Thomas et al., “Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation,” Oncogene, vol. 29, no. 37, pp. 5135–5145, 2010. View at Publisher · View at Google Scholar
  104. M. L. Gillison, “Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity,” Seminars in Oncology, vol. 31, no. 6, pp. 744–754, 2004. View at Publisher · View at Google Scholar · View at Scopus
  105. J. Califano, P. van der Riet, W. Westra et al., “Genetic progression model for head and neck cancer: implications for field cancerization,” Cancer Research, vol. 56, no. 11, pp. 2488–2492, 1996. View at Google Scholar · View at Scopus
  106. K. L. Richards, B. Zhang, K. A. Baggerly et al., “Genome-wide hypomethylation in head and neck cancer is more pronounced in HPV-negative tumors and is associated with genomic instability,” PLoS One, vol. 4, no. 3, Article ID e4941, 2009. View at Publisher · View at Google Scholar
  107. J. Woenckhaus, K. Steger, E. Werner et al., “Genomic gain of PIK3CA and increased expression of pI I 0alpha are associated with progression of dysplasia into invasive squamous cell carcinoma,” Journal of Pathology, vol. 198, no. 3, pp. 335–342, 2002. View at Publisher · View at Google Scholar · View at Scopus
  108. J. R. Grandis, S. D. Drenning, A. Chakraborty et al., “Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro,” The Journal of Clinical Investigation, vol. 102, no. 7, pp. 1385–1392, 1998. View at Google Scholar
  109. R. J. Leeman, V. W. Y. Lui, and J. R. Grandis, “STAT3 as a therapeutic target in head and neck cancer,” Expert Opinion on Biological Therapy, vol. 6, no. 3, pp. 231–241, 2006. View at Publisher · View at Google Scholar · View at Scopus
  110. M. Masuda, M. Suzui, R. Yasumatu et al., “Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma,” Cancer Research, vol. 62, no. 12, pp. 3351–3355, 2002. View at Google Scholar · View at Scopus
  111. L. J. Clark, K. Edington, I. R. C. Swan et al., “The absence of Harvey ras mutations during development and progression of squamous cell carcinomas of the head and neck,” British Journal of Cancer, vol. 68, no. 3, pp. 617–620, 1993. View at Google Scholar
  112. D. Saranath, S. E. Chang, L. T. Bhoite et al., “High frequency mutation in codons 12 and 61 of H-ras oncogene in chewing tobacco-related human oral carcinoma in India,” British Journal of Cancer, vol. 63, no. 4, pp. 573–578, 1991. View at Google Scholar
  113. J. A. Engelman, J. I. Luo, and L. C. Cantley, “The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism,” Nature Reviews Genetics, vol. 7, no. 8, pp. 606–619, 2006. View at Publisher · View at Google Scholar · View at Scopus
  114. S. Scarpino, F. C. d'Alena, A. Di Napoli, A. Pasquini, A. Marzullo, and L. P. Ruco, “Increased expression of Met protein is associated with up-regulation of hypoxia inducible factor-I (HIF-I) in tumour cells in papillary carcinoma of the thyroid,” Journal of Pathology, vol. 202, no. 3, pp. 352–358, 2004. View at Publisher · View at Google Scholar · View at Scopus
  115. L. Xu, M. B. Nilsson, P. Saintigny et al., “Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1α in non-small cell lung cancer cells,” Oncogene, vol. 29, no. 18, pp. 2616–2627, 2010. View at Publisher · View at Google Scholar
  116. S. Pennacchietti, P. Michieli, M. Galluzzo, M. Mazzone, S. Giordano, and P. M. Comoglio, “Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene,” Cancer Cell, vol. 3, no. 4, pp. 347–361, 2003. View at Publisher · View at Google Scholar · View at Scopus
  117. C. W. Pugh and P. J. Ratcliffe, “Regulation of angiogenesis by hypoxia: role of the HIF system,” Nature Medicine, vol. 9, no. 6, pp. 677–684, 2003. View at Publisher · View at Google Scholar · View at Scopus
  118. S. Hara, K. I. Nakashiro, S. K. Klosek, T. Ishikawa, S. Shintani, and H. Hamakawa, “Hypoxia enhances c-Met/HGF receptor expression and signaling by activating HIF-1α in human salivary gland cancer cells,” Oral Oncology, vol. 42, no. 6, pp. 593–598, 2006. View at Publisher · View at Google Scholar · View at Scopus
  119. A. Chakravarti, J. S. Loeffler, and N. J. Dyson, “Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling,” Cancer Research, vol. 62, no. 1, pp. 200–207, 2002. View at Google Scholar